Oncology

Sanofi’s Isatuximab combo extends lives in multiple myeloma Phase III trials of Sanofi’s investigational anti-CD38 monoclonal antibody, isatuximab combination therapy were successful in lowering down the multiple myeloma tumor rate in 60% of the patients in comparison to 35% reduction in the patients taking the standard therapy consisting pomalidomide and dexamethasone only. There exist several treatment options for multiple myeloma but still, it is incurable as the patient eventually go into remission and relapses. BLU-667 drug shrinks 60% of lung cancers Blueprint Medicines’ RET inhibitor BLU-667 shrank tumor rate in 60% of a difficult-to-treat group of l...